Biosimilars EMA-based H5O

The Biosimilars EMA-based H5O app offers a digital, fast, simple and up-to-date access to extensive information on biosimilars. The app was developed in cooperation with interdisciplinary experts in order to be able to guarantee a comprehensive and up-to-date overview of the topic of biosimilars. The app presents educational content, prepared in a modern way.

The app includes the following content:

• Biosimilars-Radar: a dynamic representation of relevant data from oncological biosimilar therapeutics.

• News: receive links to the latest news, such as regulatory information from authorities, or new, interesting publications on the subject of biosimilars.

• Manufacture, safety and approval of biosimilars: Concise and brief explanations on the most important topics can be found in our educative app.

• Statements: references to the latest statements from professional societies, commissions and authorities.

• Glossary: the most important terms relating to biosimilars are explained in the glossary. The quick introduction into the world of biosimilars.

• The app content is based on EMA processes / approvals.

The "Biosimilar-Radar" section of V1.0 is limited to the oncological therapeutics and also presents the reference product there. In addition to approval status and effectiveness data, safety data are also presented. This gives you quick and uncomplicated access to relevant data - of course with relevant literature quoted and a detailed list of references.

The app serves solely as a basis for information. It is only intended for health-care professionals (HCP) with a high5oncology (H5O) login.

Note: the screenshots shown are dated 10/19/2022 and are only used to illustrate the presentation of the content. They do not represent the current status of the app.